Compare · AEON vs NVO
AEON vs NVO
Side-by-side comparison of AEON Biopharma Inc. (AEON) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEON and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $174.57B, about 17424.3x AEON ($10.0M).
- AEON has been more active in the news (11 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for AEON).
- Company
- AEON Biopharma Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $10.0M
- $174.57B
- 1M return
- -
- +0.27%
- 1Y return
- -
- -19.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 11
- 9
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AEON
- SEC Form SCHEDULE 13G filed by AEON Biopharma Inc.
- SEC Form 10-Q filed by AEON Biopharma Inc.
- AEON Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by AEON Biopharma Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by AEON Biopharma Inc.
- Large owner Daewoong Co., Ltd exercised 11,236,631 in-the-money shares at a strike of $0.00 and disposed of $1,124 worth of shares (3,822 units at $0.29) (SEC Form 4)
- AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
- AEON Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B3 filed by AEON Biopharma Inc.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S